Q-omics provides the consensus-scored BEND6 profile across patient tissues and cancer cell-line models. BEND6 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, BEND6 is differentially expressed in 13, with the highest sampling consensus in LUAD. Additionally, BEND6 RNA expression shows 19,219 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, LUAD, and UVM as cancer lineages where BEND6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BEND6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BEND6 survival associations across molecular data types. BEND6 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BEND6 RNA expression–survival associations across cancer types. High BEND6 expression shows unfavorable associations in MESO, UCEC, BLCA, ACC, KIRC and UVM. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for BEND6 RNA expression.
This table summarizes BEND6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for BEND6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BEND6 shows lower tumor expression in UCEC and BLCA and higher tumor expression in LUAD, HNSC, KIRP and LUSC. The LUAD box plot shows higher BEND6 RNA expression in tumor versus normal tissue (log2 FC = +1.430, t-test p < 0.001).
This table shows molecular features associated with BEND6 in patient tissues and cancer cell lines. In patient samples, BEND6 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, BEND6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and CNS.
